Navar AM, Pencina MJ, Rymer JA, et al. Use of open access platforms for clinical trial data. (Letter). JAMA 2016;315(12):1283-1284
(doi: 10.1001/jama.2016.2374)
Concerns over bias in clinical trial reporting have stimulated calls for more open data sharing. In response, multiple pharmaceutical companies have created mechanisms for investigators to access patient-level clinical trials data. Although more than 3,000 trials are available to investigators through open data platforms, only 15.5% had been requested by a limited number of researchers. Availability of shared clinical trial data should be promoted and use of individual patient data for validation studies encouraged.
http://jama.jamanetwork.com/article.aspx?articleid=2504799
(doi: 10.1001/jama.2016.2374)
Concerns over bias in clinical trial reporting have stimulated calls for more open data sharing. In response, multiple pharmaceutical companies have created mechanisms for investigators to access patient-level clinical trials data. Although more than 3,000 trials are available to investigators through open data platforms, only 15.5% had been requested by a limited number of researchers. Availability of shared clinical trial data should be promoted and use of individual patient data for validation studies encouraged.
http://jama.jamanetwork.com/article.aspx?articleid=2504799
Comments